{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T02:00:11Z","timestamp":1775008811898,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T00:00:00Z","timestamp":1726531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T00:00:00Z","timestamp":1726531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s00774-024-01553-z","type":"journal-article","created":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T14:12:46Z","timestamp":1726668766000},"page":"741-753","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Real-life effects of pharmacological osteoporosis treatments on bone mineral density by quantitative computed tomography"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9967-3542","authenticated-orcid":false,"given":"Elena","family":"Boehm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Baur-Melnyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna Theresia","family":"Biebl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saori","family":"Harada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"Wegener","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduard","family":"Kraft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isa","family":"Feist-Pagenstert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,17]]},"reference":[{"key":"1553_CR1","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3171\/2022.11.SPINE22875","volume":"38","author":"N Deshpande","year":"2023","unstructured":"Deshpande N, Hadi MS, Lillard JC, Passias PG, Linzey JR, Saadeh YS, LaBagnara M, Park P (2023) Alternatives to DEXA for the assessment of bone density: a systematic review of the literature and future recommendations. J Neurosurg Spine 38:436\u2013445. https:\/\/doi.org\/10.3171\/2022.11.SPINE22875","journal-title":"J Neurosurg Spine"},{"key":"1553_CR2","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/895474","author":"N Li","year":"2013","unstructured":"Li N, Li XM, Xu L, Sun WJ, Cheng XG, Tian W (2013) Comparison of QCT and DXA: osteoporosis detection rates in postmenopausal women. Int J Endocrinol. https:\/\/doi.org\/10.1155\/2013\/895474","journal-title":"Int J Endocrinol"},{"key":"1553_CR3","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa031975","volume":"349","author":"DM Black","year":"2003","unstructured":"Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207\u20131215. https:\/\/doi.org\/10.1056\/NEJMoa031975","journal-title":"N Engl J Med"},{"key":"1553_CR4","doi-asserted-by":"publisher","first-page":"564","DOI":"10.4158\/GL-2020-0524","volume":"26","author":"PM Camacho","year":"2020","unstructured":"Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A, Harris ST, Hurley DL, Kelly J, Lewiecki EM, Pessah-Pollack R, McClung M, Wimalawansa SJ, Watts NB (2020) American Association of Clinical Endocrinologists\/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis\u2014 2020 update executive summary. Endocr Pract 26:564\u2013570. https:\/\/doi.org\/10.4158\/GL-2020-0524","journal-title":"Endocr Pract"},{"key":"1553_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jocd.2007.12.010","volume":"11","author":"K Engelke","year":"2008","unstructured":"Engelke K, Adams JE, Armbrecht G, Augat P, Bogado CE, Bouxsein ML, Felsenberg D, Ito M, Prevrhal S, Hans DB, Lewiecki EM (2008) Clinical use of quantitative computed tomography and peripheral quantitative computed tomography in the management of osteoporosis in adults: the 2007 ISCD official positions. J Clin Densitom 11:123\u2013162. https:\/\/doi.org\/10.1016\/j.jocd.2007.12.010","journal-title":"J Clin Densitom"},{"key":"1553_CR6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrendo.2011.146","volume":"8","author":"JS Chen","year":"2012","unstructured":"Chen JS, Sambrook PN (2012) Antiresorptive therapies for osteoporosis: a clinical overview. Nat Rev Endocrinol 8:81\u201391. https:\/\/doi.org\/10.1038\/nrendo.2011.146","journal-title":"Nat Rev Endocrinol"},{"key":"1553_CR7","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1080\/13697137.2021.1953463","volume":"25","author":"MR McClung","year":"2022","unstructured":"McClung MR, Clark AL (2022) Osteoanabolic therapy for osteoporosis in women. Climacteric 25:60\u201366. https:\/\/doi.org\/10.1080\/13697137.2021.1953463","journal-title":"Climacteric"},{"key":"1553_CR8","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/s41574-023-00866-9","volume":"19","author":"I Foessl","year":"2023","unstructured":"Foessl I, Dimai HP, Obermayer-Pietsch B (2023) Long-term and sequential treatment for osteoporosis. Nat Rev Endocrinol 19:520\u2013533. https:\/\/doi.org\/10.1038\/s41574-023-00866-9","journal-title":"Nat Rev Endocrinol"},{"key":"1553_CR9","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1089\/15246090050118125","volume":"9","author":"E Siris","year":"2000","unstructured":"Siris E (2000) Alendronate in the treatment of osteoporosis: a review of the clinical trials. J Womens Health Gend Based Med 9:599\u2013606. https:\/\/doi.org\/10.1089\/15246090050118125","journal-title":"J Womens Health Gend Based Med"},{"key":"1553_CR10","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, Martin JS, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u2013765. https:\/\/doi.org\/10.1056\/NEJMoa0809493","journal-title":"N Engl J Med"},{"key":"1553_CR11","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s00774-019-01049-1","volume":"38","author":"K Iba","year":"2020","unstructured":"Iba K, Takada J, Sonoda T, Yamashita T (2020) Effect of continuous long-term treatment for 10 years with bisphosphonate on Japanese osteoporosis patients. J Bone Miner Metab 38:240\u2013247. https:\/\/doi.org\/10.1007\/s00774-019-01049-1","journal-title":"J Bone Miner Metab"},{"key":"1553_CR12","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1007\/s00198-015-3234-7","volume":"26","author":"S Papapoulos","year":"2015","unstructured":"Papapoulos S, Lippuner K, Roux C, Lin CJF, Kendler DL et al (2015) The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporos Int 26:2773\u20132783. https:\/\/doi.org\/10.1007\/s00198-015-3234-7","journal-title":"Osteoporos Int"},{"key":"1553_CR13","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","volume":"386","author":"BZ Leder","year":"2015","unstructured":"Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie S-AM (2015) Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. The Lancet 386:1147\u20131155. https:\/\/doi.org\/10.1016\/S0140-6736(15)61120-5","journal-title":"The Lancet"},{"key":"1553_CR14","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1016\/j.bone.2010.03.003","volume":"46","author":"K Engelke","year":"2010","unstructured":"Engelke K, Fuerst T, Dasic G, Davies RY, Genant HK (2010) Regional distribution of spine and hip QCT BMD responses after one year of once-monthly ibandronate in postmenopausal osteoporosis. Bone 46:1626\u20131632. https:\/\/doi.org\/10.1016\/j.bone.2010.03.003","journal-title":"Bone"},{"key":"1553_CR15","doi-asserted-by":"publisher","first-page":"e2690","DOI":"10.1210\/clinem\/dgac232","volume":"107","author":"S Agarwal","year":"2022","unstructured":"Agarwal S, Shane E, Lang T, Shiau S, Kamanda-Kosseh M, Bucovsky M, Lappe JM, Stubby J, Recker RR, Hu Y, Wang Z, Edward Guo X, Cohen A (2022) Spine volumetric BMD and strength in premenopausal idiopathic osteoporosis: effect of teriparatide followed by denosumab. J Clin Endocrinol Metab 107:e2690\u2013e2701. https:\/\/doi.org\/10.1210\/clinem\/dgac232","journal-title":"J Clin Endocrinol Metab"},{"key":"1553_CR16","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.bone.2013.07.011","volume":"56","author":"HK Genant","year":"2013","unstructured":"Genant HK, Libanati C, Engelke K, Zanchetta JR, H\u00f8iseth A, Yuen CK, Stonkus S, Bolognese MA, Franek E, Fuerst T, Radcliffe H-S, McClung MR (2013) Improvements in hip trabecular, subcortical, and cortical density and mass in postmenopausal women with osteoporosis treated with denosumab. Bone 56:482\u2013488. https:\/\/doi.org\/10.1016\/j.bone.2013.07.011","journal-title":"Bone"},{"key":"1553_CR17","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/jbmr.2932","volume":"32","author":"HK Genant","year":"2017","unstructured":"Genant HK, Engelke K, Bolognese MA, Mautalen C, Brown JP, Recknor C, Goemaere S, Fuerst T, Yang Y, Grauer A, Libanati C (2017) Effects of romosozumab compared with teriparatide on bone density and mass at the spine and hip in postmenopausal women with low bone mass. J Bone Miner Res 32:181\u2013187. https:\/\/doi.org\/10.1002\/jbmr.2932","journal-title":"J Bone Miner Res"},{"key":"1553_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2021.101090","volume":"14","author":"K Tsuchiya","year":"2021","unstructured":"Tsuchiya K, Ishikawa K, Kudo Y, Tani S, Nagai T, Toyone T, Inagaki K (2021) Analysis of the subsequent treatment of osteoporosis by transitioning from bisphosphonates to denosumab, using quantitative computed tomography: a prospective cohort study. Bone Rep 14:101090. https:\/\/doi.org\/10.1016\/j.bonr.2021.101090","journal-title":"Bone Rep"},{"key":"1553_CR19","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/jbmr.4259","volume":"36","author":"SK Ramchand","year":"2021","unstructured":"Ramchand SK, David NL, Lee H, Eastell R, Tsai JN, Leder BZ (2021) Efficacy of zoledronic acid in maintaining areal and volumetric bone density after combined denosumab and teriparatide administration: DATA-HD study extension. J Bone Miner Res 36:921\u2013930. https:\/\/doi.org\/10.1002\/jbmr.4259","journal-title":"J Bone Miner Res"},{"key":"1553_CR20","doi-asserted-by":"publisher","first-page":"71","DOI":"10.52628\/89.1.9808","volume":"89","author":"S-J Kim","year":"2023","unstructured":"Kim S-J, Lee D-W (2023) A retrospective analysis of nonresponse to denosumab after hip fractures. Acta Orthop Belg 89:71\u201376. https:\/\/doi.org\/10.52628\/89.1.9808","journal-title":"Acta Orthop Belg"},{"key":"1553_CR21","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1185\/030079904X16768","volume":"20","author":"AI Sebba","year":"2004","unstructured":"Sebba AI, Lou BS, Kagan R, Thompson DE, Skalky CS, Chen E, de Papp AE (2004) Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis. Curr Med Res Opin 20:2031\u20132041. https:\/\/doi.org\/10.1185\/030079904X16768","journal-title":"Curr Med Res Opin"},{"key":"1553_CR22","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1080\/17843286.2023.2238375","volume":"78","author":"V Konings","year":"2023","unstructured":"Konings V, Laurent MR, Janssens S, Dupont J, Gielen E, Dejaeger M (2023) Skeletal response to teriparatide in real-life setting: effects of age, baseline bone density and prior denosumab use. Acta Clin Belg 78:446\u2013451. https:\/\/doi.org\/10.1080\/17843286.2023.2238375","journal-title":"Acta Clin Belg"},{"key":"1553_CR23","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1258\/136218004774202409","volume":"10","author":"RM Francis","year":"2004","unstructured":"Francis RM (2004) Non-response to osteoporosis treatment. Br Menopause Soc J 10:76\u201380. https:\/\/doi.org\/10.1258\/136218004774202409","journal-title":"Br Menopause Soc J"},{"key":"1553_CR24","doi-asserted-by":"publisher","first-page":"E258","DOI":"10.1097\/BRS.0000000000004224","volume":"47","author":"AG Kulkarni","year":"2022","unstructured":"Kulkarni AG, Thonangi Y, Pathan S, Gunjotikar S, Goparaju P, Talwar I, Jaggi S, Shah S, Shah N, Kursija G (2022) Should Q-CT be the gold standard for detecting spinal osteoporosis? Spine (Phila Pa 1976) 47:E258\u2013E264. https:\/\/doi.org\/10.1097\/BRS.0000000000004224","journal-title":"Spine (Phila Pa 1976)"},{"key":"1553_CR25","volume-title":"Linear Mixed Models for Longitudinal Data","author":"G Verbeke","year":"2009","unstructured":"Verbeke G, Molenberghs G (2009) Linear Mixed Models for Longitudinal Data. Springer"},{"key":"1553_CR26","unstructured":"R Core Team (2021) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https:\/\/www.R-project.org\/"},{"key":"1553_CR27","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2023.10.008","author":"M Chen","year":"2023","unstructured":"Chen M, Gerges M, Raynor WY, Park PSU, Nguyen E, Chan DH, Gholamrezanezhad A (2023) State of the art imaging of osteoporosis. Semin Nucl Med. https:\/\/doi.org\/10.1053\/j.semnuclmed.2023.10.008","journal-title":"Semin Nucl Med"},{"key":"1553_CR28","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1385\/JCD:5:2:193","volume":"5","author":"DD Cherney","year":"2002","unstructured":"Cherney DD, Laymon MS, McNitt A, Yuly S (2002) A study on the influence of calcified intervertebral disk and aorta in determining bone mineral density. J Clin Densitom 5:193\u2013198. https:\/\/doi.org\/10.1385\/JCD:5:2:193","journal-title":"J Clin Densitom"},{"key":"1553_CR29","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1210\/jcem-70-4-1202","volume":"70","author":"ES Orwoll","year":"1990","unstructured":"Orwoll ES, Oviatt SK, Mann T (1990) The impact of osteophytic and vascular calcifications on vertebral mineral density measurements in men*. J Clin Endocrinol Metab 70:1202\u20131207. https:\/\/doi.org\/10.1210\/jcem-70-4-1202","journal-title":"J Clin Endocrinol Metab"},{"key":"1553_CR30","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jocd.2012.02.014","volume":"16","author":"MR McClung","year":"2013","unstructured":"McClung MR, Zanchetta JR, H\u00f8iseth A, Kendler DL, Yuen CK, Brown JP, Stonkus S, Goemaere S, Recknor C, Woodson GC, Bolognese MA, Franek E, Brandi ML, Wang A, Libanati C (2013) Denosumab densitometric changes assessed by quantitative computed tomography at the spine and hip in postmenopausal women with osteoporosis. J Clin Densitom 16:250\u2013256. https:\/\/doi.org\/10.1016\/j.jocd.2012.02.014","journal-title":"J Clin Densitom"},{"key":"1553_CR31","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/j.acra.2017.06.013","volume":"24","author":"SS Mao","year":"2017","unstructured":"Mao SS, Li D, Syed YS, Gao Y, Luo Y, Flores F, Child J, Cervantes M, Kalantar-Zadeh K, Budoff MJ (2017) Thoracic quantitative computed tomography (QCT) can sensitively monitor bone mineral metabolism. Acad Radiol 24:1582\u20131587. https:\/\/doi.org\/10.1016\/j.acra.2017.06.013","journal-title":"Acad Radiol"},{"key":"1553_CR32","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1210\/jc.2011-0385","volume":"96","author":"MF Holick","year":"2011","unstructured":"Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM (2011) Evaluation, Treatment, and prevention of Vitamin D deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 96:1911\u20131930. https:\/\/doi.org\/10.1210\/jc.2011-0385","journal-title":"J Clin Endocrinol Metab"},{"key":"1553_CR33","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s11657-018-0524-7","volume":"13","author":"JS Lee","year":"2018","unstructured":"Lee JS, Kim JW (2018) Prevalence of vitamin D deficiency in postmenopausal high- and low-energy fracture patient. Arch Osteoporos 13:109. https:\/\/doi.org\/10.1007\/s11657-018-0524-7","journal-title":"Arch Osteoporos"},{"key":"1553_CR34","doi-asserted-by":"publisher","first-page":"4148","DOI":"10.3390\/nu14194148","volume":"14","author":"F Bertoldo","year":"2022","unstructured":"Bertoldo F, Cianferotti L, Di Monaco M, Falchetti A, Fassio A, Gatti D, Gennari L, Giannini S, Girasole G, Gonnelli S, Malavolta N, Minisola S, Pedrazzoni M, Rendina D, Rossini M, Chiodini I (2022) Definition, assessment, and management of vitamin D inadequacy: suggestions, recommendations, and warnings from the italian society for osteoporosis, mineral metabolism and bone diseases (SIOMMMS). Nutrients 14:4148. https:\/\/doi.org\/10.3390\/nu14194148","journal-title":"Nutrients"},{"key":"1553_CR35","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1007\/s00198-011-1868-7","volume":"23","author":"AS Carmel","year":"2012","unstructured":"Carmel AS, Shieh A, Bang H, Bockman RS (2012) The 25(OH)D level needed to maintain a favorable bisphosphonate response is \u226533 ng\/ml. Osteoporos Int 23:2479\u20132487. https:\/\/doi.org\/10.1007\/s00198-011-1868-7","journal-title":"Osteoporos Int"},{"key":"1553_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115516","volume":"139","author":"B Langdahl","year":"2020","unstructured":"Langdahl B (2020) Treatment of postmenopausal osteoporosis with bone-forming and antiresorptive treatments: combined and sequential approaches. Bone 139:115516. https:\/\/doi.org\/10.1016\/j.bone.2020.115516","journal-title":"Bone"},{"key":"1553_CR37","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1185\/03007990802466595","volume":"24","author":"H Minne","year":"2008","unstructured":"Minne H, Audran M, Sim\u00f5es ME, Obermayer-Pietsch B, Sigur\u00f0sson G, Mar\u00edn F, Dalsky GP, Nickelsen T (2008) Bone density after teriparatide in patients with or without prior antiresorptive treatment: one-year results from the EUROFORS study*. Curr Med Res Opin 24:3117\u20133128. https:\/\/doi.org\/10.1185\/03007990802466595","journal-title":"Curr Med Res Opin"},{"key":"1553_CR38","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","volume":"18","author":"E Orwoll","year":"2003","unstructured":"Orwoll E, Scheele W, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman J-M, Clancy A, Gaich G (2003) The Effect of teriparatide [Human Parathyroid Hormone (1\u201334)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18:9\u201317. https:\/\/doi.org\/10.1359\/jbmr.2003.18.1.9","journal-title":"J Bone Miner Res"},{"key":"1553_CR39","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1210\/jc.2008-1807","volume":"94","author":"EM Lewiecki","year":"2009","unstructured":"Lewiecki EM, Keaveny TM, Kopperdahl DL, Genant HK, Engelke K, Fuerst T, Kivitz A, Davies RY, Fitzpatrick LA (2009) Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 94:171\u2013180. https:\/\/doi.org\/10.1210\/jc.2008-1807","journal-title":"J Clin Endocrinol Metab"},{"key":"1553_CR40","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1186\/s13018-021-02678-x","volume":"16","author":"F Migliorini","year":"2021","unstructured":"Migliorini F, Maffulli N, Colarossi G, Eschweiler J, Tingart M, Betsch M (2021) Effect of drugs on bone mineral density in postmenopausal osteoporosis: a Bayesian network meta-analysis. J Orthop Surg Res 16:533. https:\/\/doi.org\/10.1186\/s13018-021-02678-x","journal-title":"J Orthop Surg Res"},{"key":"1553_CR41","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1385\/JCD:6:4:307","volume":"6","author":"EM Lewiecki","year":"2003","unstructured":"Lewiecki EM (2003) Nonresponders to osteoporosis therapy. J Clin Densitom 6:307\u2013314. https:\/\/doi.org\/10.1385\/JCD:6:4:307","journal-title":"J Clin Densitom"},{"key":"1553_CR42","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.maturitas.2004.02.005","volume":"48","author":"JS McCombs","year":"2004","unstructured":"McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J (2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48:271\u2013287. https:\/\/doi.org\/10.1016\/j.maturitas.2004.02.005","journal-title":"Maturitas"},{"key":"1553_CR43","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/ncprheum0928","volume":"4","author":"EM Lewiecki","year":"2008","unstructured":"Lewiecki EM, Lane NE (2008) Common mistakes in the clinical use of bone mineral density testing. Nat Clin Pract Rheumatol 4:667\u2013674. https:\/\/doi.org\/10.1038\/ncprheum0928","journal-title":"Nat Clin Pract Rheumatol"},{"key":"1553_CR44","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.bone.2018.08.024","volume":"120","author":"T Damm","year":"2019","unstructured":"Damm T, Pe\u00f1a JA, Campbell GM, Bastgen J, Barkmann R, Gl\u00fcer C-C (2019) Improved accuracy in the assessment of vertebral cortical thickness by quantitative computed tomography using the Iterative Convolution OptimizatioN (ICON) method. Bone 120:194\u2013203. https:\/\/doi.org\/10.1016\/j.bone.2018.08.024","journal-title":"Bone"},{"key":"1553_CR45","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1002\/jbmr.287","volume":"26","author":"BA Christiansen","year":"2011","unstructured":"Christiansen BA, Kopperdahl DL, Kiel DP, Keaveny TM, Bouxsein ML (2011) Mechanical contributions of the cortical and trabecular compartments contribute to differences in age-related changes in vertebral body strength in men and women assessed by QCT-based finite element analysis. J Bone Miner Res 26:974\u2013983. https:\/\/doi.org\/10.1002\/jbmr.287","journal-title":"J Bone Miner Res"},{"key":"1553_CR46","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jocd.2012.02.006","volume":"16","author":"MA Bolognese","year":"2013","unstructured":"Bolognese MA, Teglbj\u00e6rg CS, Zanchetta JR, Lippuner K, McClung MR, Brandi ML, H\u00f8iseth A, Lakatos P, Moffett AH, Lorenc RS, Wang A, Libanati C (2013) denosumab significantly increases dxa bmd at both trabecular and cortical sites: results from the FREEDOM study. J Clin Densitom 16:147\u2013153. https:\/\/doi.org\/10.1016\/j.jocd.2012.02.006","journal-title":"J Clin Densitom"},{"key":"1553_CR47","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. The Lancet 348:1535\u20131541. https:\/\/doi.org\/10.1016\/S0140-6736(96)07088-2","journal-title":"The Lancet"},{"key":"1553_CR48","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.bone.2018.07.013","volume":"116","author":"BL Langdahl","year":"2018","unstructured":"Langdahl BL, Silverman S, Fujiwara S, Saag K, Napoli N, Soen S, Enomoto H, Melby TE, Disch DP, Marin F, Krege JH (2018) Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: Integrated analysis of 4 prospective observational studies. Bone 116:58\u201366. https:\/\/doi.org\/10.1016\/j.bone.2018.07.013","journal-title":"Bone"},{"key":"1553_CR49","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s11910-017-0723-4","volume":"17","author":"TP Garcia","year":"2017","unstructured":"Garcia TP, Marder K (2017) Statistical approaches to longitudinal data analysis in neurodegenerative diseases: Huntington\u2019s disease as a model. Curr Neurol Neurosci Rep 17:14. https:\/\/doi.org\/10.1007\/s11910-017-0723-4","journal-title":"Curr Neurol Neurosci Rep"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-024-01553-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00774-024-01553-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-024-01553-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T07:38:12Z","timestamp":1733902692000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00774-024-01553-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,17]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["1553"],"URL":"https:\/\/doi.org\/10.1007\/s00774-024-01553-z","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,17]]},"assertion":[{"value":"10 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the responsible local Ethics Committee of Ludwig Maximilian University of Munich (no. 20\u20131126; date: 28.04.2021).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included prospectively in the study. The study was retrospectively registered in the Federal Institute for Drugs and Medical Devices on 06.10.2022 under the ID DRKS00024124.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent and research involving human and animal participants"}}]}}